Lenalidomide maintenance following tandem autologous stem cell and non myeloablative allogeneic transplantation for patients with multiple myeloma <= 66 years who have been treated in or according to the HOVON 65/GMMG-HD4 study.

Trial Profile

Lenalidomide maintenance following tandem autologous stem cell and non myeloablative allogeneic transplantation for patients with multiple myeloma <= 66 years who have been treated in or according to the HOVON 65/GMMG-HD4 study.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 07 Jul 2011

At a glance

  • Drugs Lenalidomide (Primary)
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jul 2011 New source identified and integrated (Netherlands Trial Register).
    • 07 Jul 2011 Additional lead trial center identified as reported by Netherlands Trial Register.
    • 07 Jul 2011 Planned end date changed from 7 Feb 2010 to 1 Apr 2010 as reported by Netherlands Trial Register.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top